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Secretin Facilitates GABA Transmission in the Cerebellum
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Secretin was the first hormone discovered in human history,
and yet, its function as a neuropeptide has been overlooked in
the past. The recent discovery of the potential use of secretin in
treating autistic patients, together with the conflicting reports
on its effectiveness, urges an in-depth investigation of this
issue. We show here that in the rat cerebellar cortex, mRNAs
encoding secretin are localized in the Purkinje cells, whereas
those of its receptor are found in both Purkinje cells and
GABAergic interneurons. Immunoreactivity for secretin is local-
ized in the soma and dendrites of Purkinje cells. In addition,
secretin facilitates evoked, spontaneous, and miniature IPSCs
recorded from Purkinje cells. We propose that secretin is re-
leased from the somatodendritic region of Purkinje cells and
serves as a retrograde messenger modulating GABAergic af-
ferent activity.
Key words: secretin; cerebellum; Purkinje cells; GABA; inhib-
itory postsynaptic currents; autism
Secretin was first discovered as a gastrointestinal hormone by
Bayliss and Starling (1902). They showed that an injection of the
upper intestinal mucosal extract into an anesthetized dog resulted
in the stimulation of pancreatic secretion and hepatic bile flow. To
date, the essential role of secretin in regulating secretion of
bicarbonate, electrolytes, and volume from pancreatic ductule
epithelial cells are firmly established (Daniel, 1991). Other ac-
tions of secretin in the digestive system include inhibition of
gastric emptying and acid output (Raybould and Holzer, 1993;
Jin et al., 1994), stimulation of hepatic bile flow (McGill et al.,
1994), and promotion of pancreatic growth (Petersen et al., 1978;
Solomon et al., 1978). However, there is still no convincing
evidence to indicate the neuroendocrine function of secretin in
the CNS, although there is some evidence to suggest that secretin
is present in the brain and is neuroactive. For example, secretin-
like bioactivity and immunoreactivity were found in mammalian
brain extracts (Mutt et al., 1979; O’Donohue et al., 1981). High-
affinity binding sites for secretin have also been detected
(Fremeau et al., 1983). Furthermore, secretin increases cAMP
concentration in a variety of brain areas (van Calker et al., 1980;
Fremeau et al., 1986). However, up to the present, neither has
Northern blot analysis detected secretin receptor transcripts in
any part of the human brain tested, namely amygdala, caudate
nucleus, corpus callosum, hippocampus, substantia nigra, subtha-
lamic nucleus, and thalamus (Chow, 1995), nor has there been any
direct electrophysiological evidence to indicate that secretin can
modulate the excitability or function of central neurons.
Recently, the question of whether secretin is neuroactive has
received a renewed attention. The reported improvement in the
behavior of autistic children receiving secretin injections supports
this idea (Horvath et al., 1998). However, there are other con-
flicting reports on the effectiveness of secretin in treating autism
(Sandler et al., 1999; Chez et al., 2000). There is also evidence to
suggest a correlation between autism and abnormalities in the
cerebellum (Courchesne, 1997; Riva and Giorgi, 2000). These
findings thus urge an in-depth investigation on the neuroendo-
crine roles of secretin, particularly the relevant neuronal pathways
and mechanisms involved in exerting its actions. In the present
study, we aim to answer these questions by examining the expres-
sion of secretin and its receptor in the rat cerebellum as well as
the in vitro electrophysiological effects of secretin on central
neurons.
MATERIALS AND METHODS
Northern blot. Poly(A) RNA was prepared from the Sprague Dawley
(SDw) rat cerebellum. Five micrograms of the Poly(A) RNA were
electrophoresed in a 1% agarose gel with 0.8% formaldehyde and trans-
blotted onto a Hybond N membrane (Amersham Pharmacia Biotech,
Arlington Heights, IL). Northern blot hybridization was performed using
32P-labeled cDNA encoding rat secretin (nucleotides 1–453) (Kopin et
al., 1990) or the N-terminal domain of the secretin receptor (nucleotides
213–639) (Ishihara et al., 1991). The partial cDNAs were produced by
RT-PCR using specific primers.
In situ hybridization histochemistry. The rat secretin and secretin re-
ceptor partial cDNAs were used to generate digoxigenin-labeled sense
and antisense riboprobes using T3 and T7 polymerases, respectively.
Cerebella from SDw rats (n  8; aged 14–16 d) were fixed with freshly
prepared 4% paraformaldehyde at 4°C for 1 hr. The fixed cerebella were
embedded in paraffin, and sagittal sections (5 m) were cut. The proce-
dures for in situ hybridization were described previously (Leung et al.,
1999). Briefly, sections were first digested with proteinase K, rinsed in 0.1
M triethanolamine, and acetylated in 0.25% acetic anhydride for 20 min
at room temperature. Prehybridization was performed by incubating
sections with 50% formamide containing 4 SSC for 30 min at 42°C.
Hybridization was performed overnight at 42°C in a humidified chamber
with antisense or sense riboprobe (20 ng/l) containing 50% formamide,
4 SSC, 0.25 mg/ml yeast tRNA, 0.25 mg/ml salmon DNA, 100 mg/ml
dextran sulfate, and 1 Denhardt’s solution. Posthybridized sections
were then washed with 2 SSC containing 50% formamide at 50°C.
Excess probe was removed by digestion with RNase A (40 g/ml) for 30
min at 37°C. Sections were finally washed sequentially with 2, 1, and
0.5 SSC at 37°C. Hybridized probes were detected with anti-
digoxigenin antibody conjugated to alkaline phosphatase (1:500) and
visualized by nitroblue-tetrazolium-chloride/5-bromo-4-chloro-indolyl-
phosphate detection kit according to the manufacturer’s instructions
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(Roche Diagnostics, Indianapolis, IN). The sections were counterstained
with methyl green, dehydrated in a graded ethanol series, and mounted
with Permount (Fisher Scientific, Tustin, CA).
Immunohistochemistry. Cerebella from SDw rats were fixed with 4%
paraformaldehyde and embedded in paraffin. Immunocytochemical
staining was performed by Vectastain ABC Elite kit (Vector Laborato-
ries, Burlingame, CA) with minor modifications. Briefly, sagittal sections
(5 m) of the cerebellum were deparaffinized by xylene, rehydrated in a
graded series of ethanol, and treated with 0.3% H2O2 in methanol for 30
min. After washing in PBS for 10 min, the sections were incubated with
5% normal goat serum for 1 hr. Excess serum was drained off, and the
sections were incubated either with rabbit anti-porcine secretin (1:1000)
(Anawa, Wangen, Switzerland), mouse anti-parvalbumin (1:500), or
mouse anti-glial acidic fibrillary protein (GFAP; 1:2000) (Chemicon,
Temecula, CA) for 24 hr at 4°C. After rinsing thoroughly in PBS, the
sections were treated with the corresponding anti-rabbit or anti-mouse
biotinylated secondary antibody (1:200) for 1 hr, followed by incubation
with the avidin–biotin–horseradish peroxidase complex reagent for 1 hr.
The presence of the immunoreactive cells in the cerebellum was detected
by 0.05% 3,3-diaminobenzidine tetrahydrochloride in 0.1 M Tris buffer.
The sections were counterstained briefly with hematoxylin or methyl
green, dehydrated, and mounted. To test the specificity of the immuno-
staining, the following controls were performed: (1) omission of the
primary or secondary antibodies or (2) liquid phase preabsorption of the
secretin antiserum with 0.1 mM porcine secretin (Peninsula Laboratories,
Belmont, CA) for 24 hr at 4°C.
Electrophysiolog ical recordings. Somatic recordings were performed
from Purkinje cells in parasagittal cerebellar slices, prepared from 14- to
16-d-old SDw rats, by a conventional patch-clamp amplifier (List Elec-
tronics, Darmstadt, Germany). Visualization of the neurons near the top
surface of the cerebellar slice was aided by infrared videomicroscopy and
differential interference contrast optics. Pipettes were pulled from boro-
silicate glasses (Sutter Instrument, Novato, CA) and had resistances from
2.2–5 M when containing the following internal solution (in mM): 140
KCl, 2 Na2-ATP, 2 MgCl2, 10 HEPES, and 1 EGTA. GTP (0.4 mM) was
freshly added to the internal solution before experimentation. The arti-
ficial CSF (ACSF) contains, in mM: 2 KCl, 120 NaCl, 2 MgSO4, 1.2
KH2PO4, 26 NaHCO3, 2.5 CaCl2, and 11 glucose. During an experi-
ment, the slices were continuously superfused with the ACSF at a rate of
1.5–2 ml/min. The temperature of the ACSF in the recording chamber
was maintained at 34  1°C by a heat-exchanger. Series resistance was
checked periodically and typically had values of 15 M. The series
resistance was not compensated, but the recording was abolished when its
value changed significantly (15%) during an experiment. The cells were
clamped at 	75 mV. Spontaneous and TTX-resistant miniature inward
synaptic currents were largely abolished by bicuculline methiodide (10
M), indicating that they were GABAA receptor-mediated. To evoke
inhibitory synaptic currents, 6-cyano-7-nitroquinoxaline-2,3-dione
(CNQX; 20 M) and ()-2-amino-5-phosphonopentanoic acid (APV; 50
M) were added to the ACSF, and currents were passed from an
ACSF-containing pipette in the molecular layer located 50–200 m from
the recording neuron. To evoke EPSCs, bicuculline (10 M) was added in
the ACSF. EPSCs originating from the parallel fiber were identified
based on their property of paired-pulse facilitation. Data were captured
on-line or off-line by the Digidata-pClamp package (Axon Instruments,
Foster City, CA) or CED Patch and Voltage Clamp Software Package
(Cambridge Electronics Design, Cambridge, UK). Automatic detection
and analysis of the spontaneous and miniature IPSCs were performed
using home-grown software. Numerical data are expressed as mean 
SEM. Comparison of the amplitude distribution of IPSCs before and
after drug treatment was made by applying the Kolmogorov–Smirnov
test; otherwise statistical tests were based on Student’s paired or un-
paired t tests, as appropriate. Drugs were obtained from the following
sources: rat secretin, forskolin (Calbiochem, La Jolla, CA); CNQX,
APV, SQ22536, 3-isobutyl-1-methylxanthine (IBMX), bicuculline me-
thiodide (Research Biochemicals, Natick, MA); vasoactive intestinal
polypeptide (VIP), pituitary adenylyl cyclase-activating polypeptide
(PACAP), Tris-GTP (Sigma, St. Louis, MO); and TTX (Alomone Labs,
Jerusalem, Israel).
RESULTS
By RT-PCR, a conspicuous expression of both secretin and se-
cretin receptors was found in the rat cerebellum (data not
shown). To confirm their expression in the cerebellum, we per-
formed Northern blot analysis using partial cDNA probes corre-
sponding to rat secretin (nucleotides 1–453) (Kopin et al., 1990)
and the secretin receptor (nucleotides 213–639) (Ishihara et al.,
1991). Positive hybridization signals for both the ligand and the
receptor were detected in the rat cerebellum (Fig. 1A). To de-
termine the cellular distributions of these transcripts, in situ
hybridization studies were performed. It was found that Purkinje
cells strongly expressed secretin and secretin receptor mRNAs
(Fig. 1B,C). To confirm the presence of secretin peptide in
Figure 1. Expression of secretin and secretin receptors in the rat cere-
bellum. A, In Northern blot analysis, positive signals for secretin and its
receptor were detected in the cerebellum. B, In in situ hybridization,
prominent secretin mRNA signals were found in Purkinje cells when
using the antisense (lef t) probe but not the sense (right) probe. C, Purkinje
cells also expressed secretin receptor mRNA. Left, Antisense probe; right,
sense probe. D, Immunoreactivity for secretin was confined to the soma
and dendrites of Purkinje cells (lef t) and was absent in consecutive control
sections (right) incubated with antiserum preabsorbed with secretin. Scale
bars: B, C, 100 m; D, 40 m. GL, Granule cell layer; ML, molecular
layer; P, Purkinje cells.
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cerebellar Purkinje cells, immunohistochemical staining was per-
formed. In agreement with the data obtained from in situ hybrid-
ization, within the cerebellar cortex, secretin immunoreactivity
was found only in Purkinje cells. Both the soma and the dendrites
of these cells were positively immunostained (Fig. 1D). In the in
situ hybridization, on closer examination, some cells in the mo-
lecular layer close to the Purkinje cells were also labeled, albeit
more weakly, with the secretin receptor probe. These cells were
found mainly in the lower half of the molecular layer, suggesting
that they were basket cells. To confirm this, we compared con-
secutive sections of the in situ hybridization staining with those of
immunostaining using antibodies against parvalbumin and
GFAP. Parvalbumin is a marker for GABA cells in the cerebellar
cortex (Kosaka et al., 1993), whereas GFAP is a marker for glia,
including Bergmann glial cells, in the cerebellum (Reichenbach et
al., 1995). Figure 2 shows the results of these stainings on con-
secutive 5 m sections of the cerebellum. Many of the small-sized
cells that were stained positively in in situ hybridization (Fig. 2B)
were also immunopositive for parvalbumin (Fig. 2A). On the
other hand, GFAP-immunopositive elements had a very different
pattern of distribution (Fig. 2C). These data suggest that basket
cells in the cerebellar cortex also express secretin receptors. On
the whole, the expression of secretin and its receptor in discrete
neuronal types in the brain strongly imply that they serve specific
neural functions. The data also suggest that, in the cerebellar
cortex, secretin, synthesized and released from the Purkinje cells,
is targeted onto basket cells and Purkinje cells themselves.
To elucidate the electrophysiological effects of secretin, we
performed whole-cell patch-clamp recordings from Purkinje cells
in rat cerebellar slices and examined the action of secretin on the
membrane current. Secretin (3–300 nM) did not cause any observ-
able change in the holding current or membrane excitability of
Purkinje cells. We next tested the effect of secretin on IPSCs
originating from interneurons and EPSCs originating from par-
allel fibers in the molecular layer (details in Materials and Meth-
ods). A brief (3–5 min) exposure to secretin (3–300 nM) resulted
in a clear increase in the amplitude and frequency of the spon-
taneous and evoked IPSCs (Fig. 3A). These actions of secretin
had an onset latency of 1–2 min in our system and were long-
lasting, typically requiring 30 min for complete recovery. In
seven cells tested, 30 nM secretin increased the amplitude of the
evoked IPSCs to 180  23% ( p 
 0.001) and that of the
spontaneous IPSCs to 162  12% ( p 
 0.001). The action of
secretin was specific to IPSCs because the EPSCs evoked by
stimulating the parallel fibers were not affected by secretin (n 
4) (Fig. 3B). The potentiation on the amplitude of the evoked
IPSCs was also accompanied by a consistent reduction in the
paired-pulse ratio (Fig. 3C). In seven cells, the mean paired-pulse
ratio decreased from 0.86  0.04 to 0.82  0.04 ( p 
 0.05)
(Fig. 3C).
The increase in the frequency of the spontaneous IPSCs sug-
gests that secretin may increase the firing of presynaptic neurons.
However, this possibility was excluded in basket cells because
secretin did not cause any change in whole-cell currents of these
cells (n  3) or their firing rate in cell-attached mode (n  3).
Nevertheless, the reduction of the paired-pulse ratio of the
evoked IPSCs indicates that the effect of secretin has a presyn-
aptic locus of action (Dobrunz and Stevens, 1997). Because a
change in the frequency of action potential-independent synaptic
currents is a well established indicator of the involvement of a
presynaptic mechanism (Van der Kloot, 1991), we examined the
effects of secretin on tetrodotoxin (TTX)-resistant, or miniature,
IPSCs. Secretin consistently increased the frequency of the min-
iature IPSCs (Fig. 4A). The effect on the amplitude was, however,
more variable. For example, at 30 nM, secretin increased the IPSC
amplitude in four of seven cells tested ( p 
 0.05; Kolmogorov–
Smirnov test). Such an increase could be attributed to an in-
creased proportion of larger events. In the rest of the cells, there
was no significant change in the amplitude. On average, there was
a 10.3  5.4% (n  7) increase in the mean amplitude of the
miniature IPSCs. The effects of various concentrations of secretin
on these parameters are summarized in Figure 4B. A clear
Figure 2. Coexpression of parvalbumin and secretin receptor mRNA in
cells in the cerebellar cortex. A, B, In these consecutive sections, parval-
bumin immunoreactivity and in situ hybridization signals were colocal-
ized in Purkinje cells and some neurons in the molecular layer. The
arrows indicate two corresponding neurons in the two sections. C, In
another consecutive section, GFAP-immunopositive cell bodies were
mainly confined in the granule cell layer and did not colocalize with cells
labeled in the in situ hybridization. Scale bar, 20 m. GL, Granule cell
layer; ML, molecular layer; P, Purkinje cell layer.
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dose-dependent relationship was apparent only in the frequency
but not the amplitude. These findings indicate that secretin in-
creases the probability of vesicular release from presynaptic ter-
minals. This process may contribute to the observed potentiation
on the amplitudes of the evoked and spontaneous IPSCs by
secretin. It should be noted that a change in the mean amplitude
of the miniature IPSCs is not necessarily inconsistent with a
presynaptic mechanism, as has been demonstrated by the presyn-
aptic effect of NMDA in the same synapse (Glitsch and Marty,
1999). For example, secretin may lead to the selective facilitation
of a subpopulation of terminals that are associated with larger
IPSC amplitudes.
The in situ hybridization data indicated that both Purkinje cells
and basket cells express secretin receptors. To address whether
secretin may increase the amplitudes of IPSCs by increasing the
sensitivity of postsynaptic GABAA receptors on Purkinje cells,
we compared the inward current induced by exogenously applied
GABA in the absence or presence of secretin. In all cells tested,
the peak inward current was not augmented by secretin; instead,
an average of 21.8 9.4% (n 6) reduction in the amplitude was
found (Fig. 4C). The response partially recovered when secretin
Figure 3. Secretin facilitates GABAergic, but not glutamatergic, synaptic
transmission in the rat cerebellum. A, Raw traces showing that evoked
and spontaneous IPSCs were augmented by bath application of 30 nM of
secretin. Paired stimuli (arrows), separated by a 50 msec interval, were
given every 4 sec. Four overlaying traces are plotted in each case. B, Top
traces on the lef t, which were averaged from 50 evoked IPSCs, revealed
that the amplitude and waveform of parallel fiber (PF)-PSC were unaf-
fected by secretin, in sharp contrast to the evoked IPSC shown in the
bottom trace. Mean data of the effect of 30 nM secretin on PF-PSCs and
evoked IPSC are shown on the right. C, On the lef t, the normalized IPSCs
from the cell shown in A and B revealed a reduction of paired-pulse ratio
(IPSC2 /IPSC1 ). Numbers in the parentheses denote the sample size. *p 

0.05 (paired t test); ***p 
 0.001 (t test).
Figure 4. Effect of secretin on miniature IPSCs and postsynaptic
GABAA receptor sensitivity of Purkinje cells. A, A typical experiment
showing that secretin increased the frequency of GABAA-mediated min-
iature IPSCs. Secretin was added to the superfusion solution for 4 min.
Two sets of traces at the time points indicated are shown on a fast
time-base. In this cell, recovery from the effect of secretin took 35 min. B,
Concentration–response curve of the effects of secretin on the frequency
(lef t) and amplitude (right) of the miniature IPSCs. A clear dose-
dependent effect was found in the frequency only. Numbers in the paren-
theses denote the number of cells tested. C, The postsynaptic sensitivity of
GABAA receptor of a Purkinje cell in the absence (lef t) or presence
(right) of 30 nM secretin was compared. Small volumes (1 l) of 0.1 mM
GABA were applied directly to the bath at a fixed distance from the
recorded cell.
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was removed. At this stage, we are not certain of the nature of this
inhibition. Nevertheless, this finding did not support the notion
that secretin has a positive modulatory effect on GABAA recep-
tors. To test if the facilitatory effects are specific to secretin, VIP
and PACAP, two structurally and pharmacologically related neu-
ropeptides, were used, but these peptides did not produce any
effect (10 nM; n  3 each). In addition, the minimal doses of
secretin needed to produce facilitation are at nanomolar concen-
trations (1–3 nM) and the EC50 value was determined to be at 14
nM, indicating the involvement of secretin receptors only (Rawl-
ings and Hezareh, 1996; Di Paolo et al., 1999). Taken together,
these observations support the idea that secretin acts via secretin
receptors expressed on basket cell terminals.
The mechanism by which secretin facilitates GABA release was
examined in another series of experiments, which were focused
on the miniature IPSCs. We first examined the possibility that
secretin facilitates vesicular release by augmenting calcium influx
(Tiaho and Nerbonne, 1996). As illustrated in Figure 5A, the
effect of secretin was not sensitive to 100 M Cd2, a broad-
spectrum blocker of voltage-dependent Ca2 channels. These
data indicate that the miniature IPSCs are facilitated by a Ca2
influx-independent mechanism. Because it is well established that
secretin increases cAMP concentration in non-neuronal target
tissues (McGill et al., 1994; Ulrich et al., 1998) and there is
evidence that it has the same action in neuronal tissues (van
Calker et al., 1980; Fremeau et al., 1986), the involvement of
cAMP as the second messenger was examined. The adenylyl
cyclase activator forskolin (10 M, n  4) and the cAMP phos-
phodiesterase inhibitor IBMX (100 M; n  3) both mimicked
the effects of secretin on the miniature IPSC frequency (data not
shown). These data were in agreement with previous studies
(Llano and Gerschenfeld, 1993; Mitoma and Konishi, 1999).
Furthermore, 20 min of preincubation of 100 M of SQ22536, an
inhibitor of the adenylyl cyclase (Lippe and Ardizzone, 1991;
Kondo and Marty, 1997), significantly reduced the effect of se-
cretin on the miniature IPSC frequency ( p 
 0.01; n  6) (Fig.
5A). SQ22536 itself did not have a clear effect on the mIPSCs.
These data, which are summarized in Figure 5B, indicate that
increased concentration of intracellular cAMP, but not influx of
Ca2, underlies the facilitatory effect of secretin on the mIPSCs.
The result, however, does not exclude the possibility that poten-
tiation of the amplitudes of the evoked and spontaneous IPSCs
involves augmentation of calcium influx via modulation of
voltage-dependent Ca2 channels or modulation of presynaptic
K conductances.
DISCUSSION
In this study, we found that secretin and its receptor are expressed
in specific neuronal populations of the cerebellar cortex. These
data are in line with previous studies showing that secretin
immunoreactivity was found in the cerebellum (O’Donohue et
al., 1981), which also has the highest secretin binding density in
the rat brain (Fremeau et al., 1983). Furthermore, we showed that
secretin selectively facilitates GABAergic inputs onto Purkinje
cells via a presynaptic and cAMP-dependent mechanism. It is
likely that the source of secretin is Purkinje cells, which express
secretin mRNA and secretin, and that the peptide acts on its own
receptors located on basket cell terminals. These novel actions of
secretin, which are distinct from those on the endocrine system
(Daniel, 1991; Nussdorfer et al., 2000), strongly support the
hypothesis that secretin serves as a neuropeptide in the rat brain.
Although secretin was the first hormone discovered in human
history, there is still no convincing evidence to indicate that
secretin, like other related members in the same peptide family
including PACAP, VIP, growth hormone releasing factor (GRF),
glucagon, and glucagon like peptide-1 (GLP-1), is also a neu-
ropeptide. Information provided by the present report represents
a new piece of the jigsaw puzzle in seeking a complete picture of
this family of brain-gut peptides, in terms of their physiology and
function.
What is the physiological role of secretin in the cerebellum?
One hypothesis that can be formulated is that after depolariza-
tion, Purkinje cells release secretin to stabilize themselves by
facilitating the inhibitory inputs from the basket cells. The pres-
ence of secretin immunoreactivity in the soma and dendrites of
Purkinje cells suggests that secretin is released in the somatoden-
dritic region. Analogous somatodendritic release has been postu-
lated for other peptides (Huang and Neher, 1996) and amino acid
transmitters (Glitsch et al., 1996; Zilberter et al., 1999). In this
context, secretin may serve as a retrograde messenger and pro-
duce effects that are opposite to those of glutamate, another
Figure 5. Mechanism of secretin-induced potentiation of miniature IP-
SCs in Purkinje cells. A, The general calcium channel blocker Cd 2 at
100 M did not attenuate the facilitatory effect of secretin on miniature
IPSC frequency (top panel ). In contrast, SQ22536, a specific inhibitor of
adenylyl cyclase, significantly reduced the effect of 30 nM secretin (bottom
panel ). B, Histogram summarizing the effects of Cd 2 and SQ22536 on
miniature IPSC frequency. Results are expressed as percentage changes
over the control value before addition of the drugs. Numbers in the
parentheses denote the number of cells tested in each case; **p 
 0.01.
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retrograde messenger postulated in the interneuron–Purkinje cell
synapse (Glitsch et al., 1996).
It has been suggested that autism is a genetic disorder (Philippe
et al., 1999). Current research links autism to biological or neu-
rological differences in the brain, for instance, abnormalities in
the structure of the brain. In fact, abnormalities in the cerebellum,
such as the size and number of Purkinje cells, have long been
suspected in the etiology of autism (Courchesne, 1997; Riva and
Giorgi, 2000). More recently, the involvement of Purkinje cells in
this disease has been supported by a rat model of autism in which
the cerebellar Purkinje cells of the virally infected brain are
selectively destroyed (Pletnikov et al., 1999). Our results therefore
provide a link for the speculative relationship between secretin,
cerebellum, and autism, as well as an explanation for the potential
use of secretin as a drug to treat this disease (Horvath et al.,
1998). Furthermore, in view of our observation that secretin and
its receptor are also expressed in other brain regions, it is ex-
pected that the electrophysiological effects of secretin are not
confined to the cerebellum.
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